Non-small cell lung cancer with MET exon 14 skip mutation: case report

BACKGROUND: Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, making up 80–85% of all lung malignancies. It can be further subdivided into different types. The three main subtypes are adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. Traditionally, NSCLCs have been treated with a combination of chemotherapy, surgery, and/or radiation therapy. However, with the advent of genotype subtype analysis and targeted therapy it has become possible to have individualized treatment options for patients with NSCLC. CASE DESCRIPTION: We present a case report of a 68-year-old female with NSCLC. Patient initially only received radiation therapy due to her not being a surgical candidate. While initial treatment was responsive, later imaging showed metastasis of disease. Subsequent genotype analysis of the patient’s tumor indicated a MET exon 14 skipping mutation which qualified her for treatment with Capmatinib (Tabrecta). CONCLUSIONS: Patients on Capmatinib have minimal side effects and better efficacy than traditional chemotherapy. Patients with MET exon 14 skipping mutations should be considered for Capmatinib therapy.